/L).
Liver enzymes were normal to slightly elevated and serology for EBV and CMV was negative. There was no lymphadenopathy and her heart, lungs and abdomen showed no abnormalities. She was thought to have either a recurrence of her MDS or an infection. Chimerism analysis was performed as previously described. 2 STR markers were selected according to the Eurochimerism panel (http://www.eurochimerism.org). Four of the 10 STR markers were informative and all showed a 100% donor signal (Figure 1 ), which argues strongly against a recurrence. Because she did not improve, her BM was examined and showed severe dysplastic changes and an increase in blasts, again consistent with MDS, type RAEB. Repeated chimerism investigation analysis again displayed a 100% donor signal, and therefore the neoplastic clone had to originate from the donor stem cells. Interestingly, karyotyping revealed 46,XX,t(3;3)(q21;q26) [6] /46,XX [14] . A third examination of blood and BM showed the same full donor chimerism results.
As the patient became transfusion dependent, her only treatment option was a second allo-SCT. Her brother, the other HLA-identical sibling, now served as a donor. Preceding the transplantation, she underwent TBI and received fludarabine. The post-transplant period consisted mainly of repeated respiratory infections without GVHD. The patient died unexpectedly 6 years after the second SCT, while in CR. She died probably due to pneumonia but no autopsy was performed. All of her three siblings remain without signs of MDS.
Structural rearrangements of the long arm of chromosome 3 have been detected in approximately 2% of patients with AML and MDS.
3 Inv(3)(q21q26) and t(3;3)(q21;q26) are among the most frequent aberrations. 3 They give rise to the so-called 3q21q26 syndrome, which is characterized by specific clinicopathological features: normal or elevated platelet counts, multilineage dysplasia, in particular dysplasia and hyperplasia of megakaryocytes, young median age, preferential involvement of females in t(3;3), and poor response to chemotherapy and poor prognosis. 4 Similarly, our patient presented with thrombocytosis and hyperplasia with dysplasia of megakaryocytes on both occasions.
Donor cell leukemia and MDS have been described after transplantation for CML, AML, ALL, and occasionally for benign hematological diseases. [5] [6] [7] Donor cell leukemia/ MDS occurring after transplantation for MDS is exceptionally rare. A literature search revealed only three such cases, two of which had a sibling donor as in our case (Table 1) . [8] [9] [10] In all cases, the second malignancy was MDS. One patient had normal cytogenetics in the primary, as well as in the donor-derived MDS. 10 The other two patients had abnormal cytogenetics that differed between the primary and the secondary MDS. 8, 9 Our case is unique in that the primary MDS as well as the donor cell MDS contained the relatively rare t(3;3)(q21;q26) cytogenetic abnormality, which is of particular interest regarding the pathogenesis of donor cell MDS/leukemia. Komrokji et al. 10 proposed several hypotheses and/or contributing factors for the development of donor cell leukemia: (1) abnormal or defective stroma and/or microenvironment, (2) genetic susceptibility, (3) immune mediated, (4) treatment related, (5) infection and (6) transfection of oncogenic material from degenerating recipient malignant cells to donor cells. Further evidence for the role of the hematopoietic microenvironment in the development of MDS was recently provided by Raaijmakers et al. 11 Microenvironmental abnormalities together with genetic susceptibility might have been the main contributing factors in our patient. Transfection of oncogenic material to donor cells is less likely to have a role because of the long period of time between the SCT and development of the donor-derived MDS. The occurrence of the same translocation in donor cells is intriguing, suggesting that this family may harbor a specific oncogenic pathway susceptibility. The 'second hit' in this family might be programmed in such manner that a specific disease with a characterizing translocation develops. From a survey of 14 patients with donor cell leukemia, Hertenstein et al. 6 concluded that the use of chemotherapy for treatment of donor cell leukemia can induce remission but that the treatment-related mortality is high, and that secondary SCT can induce long-lasting remission in some patients. Successful reduced-intensity BMT from an alternative, unrelated donor after donor-derived MDS has been described, 9 as well as the response of donor cell MDS to donor lymphocyte infusion. 10 
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